Browse by Medical Category
Dr. Dienstag’s research efforts have focused on antiviral therapy for chronic viral hepatitis. He has participated in clinical trials of the major antiviral therapies for chronic hepatitis B and C, beginning with interferon monotherapy and culminating for hepatitis B in nucleoside analogs and for hepatitis C in the highly effective direct-acting antivirals available today. Between 2000 and 2010, he was the clinical center site-PI of a national, NIDDK-supported trial of maintenance antiviral therapy for patients refractory to treatment for chronic hepatitis C, the Hepatitis C Antiviral Long-term Treatment against Cirrhosis (HALT-C) Trial. Beginning in 2003, he studied novel polymerase and protease inhibitors for hepatitis C. Currently, he is a coinvestigator in the NIDDK-supported Harvard Medical School Hepatitis B Clinical Research Network – Clinical Center. In addition, he is chairman of the Harvard Medical School Catalyst Human Research Center Advisory Committee (Clinical Translational Science Center) and serves on data safety monitoring boards and data monitoring committees for ongoing clinical trials.
Ongoing Research Projects
Selected Peer-reviewed Publications
Back to Top